$STOCK UNDERGROUND$

[Robertscott]

$NBIO "The Company is moving forward as expected with our Phase I Clinical Trial. In the process, we are learning a lot about PTB. We believe that, as we progress forward with the phase I Clinical Trial and move into phase II, achievement of our milestones will drive significant value for the Company and our shareholders."

Pritumumab (PTB) is a unique monoclonal antibody that attacks cancers originating in epithelial cells - the cells that line the organs of the body.

During the interview Mr. Carrick updated current and prospective shareholders on recent milestones achieved by the Company including:

Nascent is at the leading edge of natural, patient-derived monoclonal antibody development with the Company's PTB monoclonal antibody solution benefitting from a well-defined regulatory and clinical development strategy toward the treatment of deadly brain cancers.

The vaccine development platform, using A recombinant Bacillus Calmette-Guerin (r-BCG), continues to progress and is intended to be used against viruses around the world.